Tissue Diagnostics Market Tissue Report
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
This report, from Stratview Research, studies the global clinical diagnostics market - tissue over the trend period of 2014 to 2017 and forecast period of 2018 to 2025. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.
The Burning Questions This Report Will Answer:
As we approach 2019, liquid biopsy is becoming a reality, for confirmatory diagnosis often repeated biopsies are needed to study the changing tumor and therefore, present a huge challenge to the patient. The process is risk prone, painful as well adds cost to the procedure. It is expected in about two years, liquid biopsy will become an adjunct to tissue biopsy. This technology has proven to be much more effective and detects worsening of a disease condition even before a CT scan, saving unnecessary medical expenses. The future of clinical diagnostics is expected to be far more connected, companies such as GE Healthcare and Roche are collaborating (January 2018) develop integrated digital diagnostics platform to improve oncology and critical care treatment.
Many multinational and domestic companies are present in this highly attractive segment. Companies like Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Cell Signaling Technology (US), Agilent Technologies (US), Merck (Germany), TissueGnostics (Austria), Sakura Finetek Japan (Japan), Abcam (UK), BD (US), QIAGEN (Netherlands), Sienna Cancer Diagnostics (Australia), Royal Philips (Netherlands), A. Menarini Diagnostics (Italy), Enzo Life Sciences (US), and more are present globally and locally.
Our reports offer high-quality insights and are the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. About 10 detailed primary interviews with the market players across the value chain in all four regions and industry experts have been executed to obtain both the qualitative and quantitative insights.
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:
The global clinical diagnostics market - tissue is segmented into the following categories:
By Product Type
By End User
With this detailed report, Stratview Research offers one of the following free customization options to our first-time clients:
Custom Research: Stratview research offers custom research services across sectors. In the case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected]